Extramedullary involvement (or extramedullary disease, EMD) represents an aggressive form of multiple myeloma (MM), characterized by the ability of a clone and/or subclone to thrive and grow independent of the bone marrow microenvironment. Several different definitions of EMD have been used in the published literature. We advocate that true EMD is restricted to soft-tissue plasmacytomas that arise due to hematogenous spread and have no contact with bony structures. Typical sites of EMD vary according to the phase of MM. At diagnosis, EMD is typically found in skin and soft tissues; at relapse, typical sites involved include liver, kidneys, lymph nodes, central nervous system (CNS), breast, pleura, and pericardium. The reported incidence of EMD varies considerably, and differences in diagnostic approach between studies are likely to contribute to this variability. In patients with newly diagnosed MM, the reported incidence ranges from 0.5% to 4.8%, while in relapsed/refractory MM the reported incidence is 3.4 to 14%. Available data demonstrate that the prognosis is poor, and considerably worse than for MM without soft-tissue plasmacytomas. Among patients with plasmacytomas, those with EMD have poorer outcomes than those with paraskeletal involvement. CNS involvement is rare, but prognosis is even more dismal than for EMD in other locations, particularly if there is leptomeningeal involvement. Available data on treatment outcomes for EMD are derived almost entirely from retrospective studies. Some agents and combinations have shown a degree of efficacy but, as would be expected, this is less than in MM patients with no extramedullary involvement. The paucity of prospective studies makes it difficult to justify strong recommendations for any treatment approach. Prospective data from patients with clearly defined EMD are important for the optimal evaluation of treatment outcomes.

Blood Cancer Journal (2022)12:45 ; https://doi.org/10.1038/s41408-022-00643-3

INTRODUCTION

Multiple myeloma (MM) is a mature B-cell neoplasm defined by the presence of ≥10% of clonal plasma cells (PCs) in the bone marrow (or plasmacytoma confirmed by biopsy) and by evidence of end-organ damage (hypercalcemia, renal insufficiency, anemia, bone lesions) caused by the PC disorder [1]. While the PC proliferation is restricted to bone marrow in most patients with MM, a subset develops soft-tissue plasmacytomas, whereby clonal PCs escape and are found outside the bone marrow.

The presence of soft-tissue plasmacytomas represents an aggressive form of MM, characterized by the ability of a clone and/or subclone to thrive and grow independent of the bone marrow microenvironment. This is linked to high-risk genetic features, increased proliferation, evasion of apoptosis, and resistance to therapies [2, 3]. There are three principal ways that soft-tissue plasmacytomas can develop in patients with MM: (a) direct growth from skeletal tumors following cortical bone disruption; (b) growth in organs or soft tissue following hematogenous spread without contact with bony structures; and (c) rarely, growth triggered by invasive procedures [4–6].

It is important to better understand soft-tissue plasmacytomas in order to successfully direct research that will improve outcomes for affected patients. This task is complicated by the fact that several different definitions of extramedullary involvement in MM, or extramedullary disease (EMD), have been used in the published literature. A 2013 study proposed that it should comprise only of purely extramedullary plasmacytomas, and exclude bone-related plasmacytomas arising from adjacent bone marrow [7]. Other authors have contended that bone-related (or paraskeletal) plasmacytomas should be included under the definition of EMD, albeit as a distinct sub-type from extramedullary plasmacytomas [8, 9]. The former definition and distinction has been endorsed by a recent expert consensus review [4]. Solitary plasmacytomas (SP) should not be considered as EMD, since they occur in the absence...
of an MM diagnosis [9, 10]. Plasma cell leukemia (PCL) is also typically excluded from the definition of EMD, on the basis that it is a well-characterized pathologic entity with distinct prognostic implications and treatment recommendations [9, 11–13]. Definitions of these different clinical entities are shown in Table 1.

Several genetic features have been linked to extramedullary involvement in MM. These include 17p deletion [14, 15], nuclear expression of p53 [16], a higher incidence of t(4;14) [17], and p53 deletion [18]. Other possible risk factors include loss of CD56 expression of p53 [16], a higher incidence of t(4;14) [17], and p53 implications and treatment recommendations [9, 11–13]. Defin-

This review is based on a systematic literature search, and will focus on hematogenous EMD, including that with central nervous system (CNS) involvement. Areas covered are incidence, sites of occurrence, prognosis, and treatment outcomes.

METHODS
The PubMed database was searched for publications of interest from January 1, 2010 to 31 December, 2020, using the following search terms: [Extramedullary AND (myeloma OR plasmacytoma)] OR [myeloma AND (bone-related OR soft tissue OR extraosseous)] OR [central nervous system AND (myeloma OR plasmacytoma OR extramedullary)]. Supplemental literature searches (for treatment outcomes) of proceedings from the following relevant conferences that took place in 2019 and 2020 were also conducted: European Haematology Association 2019 and 2020; American Society of Clinical Oncology 2019 and 2020; American Society of Hematology 2019 and 2020; International Myeloma Working Group 2019.

Following a check for duplicates, retrieved records (titles and abstracts) were screened to exclude those clearly not relevant for inclusion. At this stage, records were excluded on the basis of the following criteria: non-English language, review articles, preclinical studies, or individual case studies/case series involving fewer than 10 patients. Full-text articles for records deemed to be possibly relevant were then obtained and reviewed for inclusion in the qualitative synthesis (given the nature of the data it was not possible or appropriate to conduct a quantitative analysis). To be included, an article needed to clearly report data for hematogenous EMD and to clearly define the phase of MM (NDMM or RRMM); it also needed to include data for one or more of the areas of interest (sites of occurrence, incidence, prognosis, treatment outcomes, CNS EMD).

RESULTS
A total of 29 articles were included in the qualitative synthesis. The PRISMA flow diagram is shown in Fig. 1.

Incidence
In some patients, EMD can be identified as visible or palpable masses; however, imaging techniques are usually needed. Both paraskeletal plasmacytomas and EMD can be found at diagnosis of MM (sometimes referred to as primary), or at relapse (secondary) [20, 22, 23]. The reported incidence varies considerably across studies, most likely due to differences in the definitions applied and the methods of evaluation. Magnetic resonance (MRI) is the best imaging approach for spinal and central nervous system (CNS) involvement. However, functional whole-body techniques should ideally be used to detect EMD. A consensus statement by the International Myeloma Working Group (IMWG) specifically recommends 18F-FDG PET/CT for this purpose [24]. Hopefully, the previous lack of standardization is solved with the recent proposal of PET/CT standardization score according to the Deauville criteria based on the analysis of two prospective studies [25]. The reported incidence of EMD at diagnosis before the PET/CT era was low, ranging from 1.7 to 4.5% [4]. With the use of PET/CT, the incidence of EMD at diagnosis is between 6 and 10% [23, 24, 26, 27], which should help to stimulate sub-studies for EMD in prospective clinical trials (such as the CASSIOPEIA study of the CASSIOPEIA trial). Finally, PET/CT should be performed in clinical practice for all patients with a suspicion of EMD, such as those with high LDH serum levels or revised stage III [4].

A number of studies have reported incidence data specifically for EMD (Table 2). A meta-analysis of eight clinical trials in patients with NDMM, involving 2332 patients, found an overall incidence of soft-tissue plasmacytomas of 11.4%, and an incidence of EMD of 0.5% [26]. The authors acknowledge that their reported incidence of EMD is likely to be an underestimation due to the imaging techniques used in the study. A study of 3744 patients with NDMM reported an overall incidence of soft-tissue plasmacytomas of 18.2%, with paraskeletal involvement in 14.5% and extramedullary involvement in 3.7% [28]. Deng et al. [18] assessed EMD in 834 consecutive MM patients from a single center in China and found incidence rates of 4.8% and 3.4% in patients with NDMM and RRMM, respectively. Another single-center study in Boston, USA, found EMP in 55/663 consecutive patients (8.3%) undergoing stem-cell transplantation [29]. Among these 55 patients, EMD was present at diagnosis in eight, at relapse in 42, and at both diagnosis and relapse in five. An analysis of 226 patients with RRMM found soft-tissue plasmacytomas in 24% of patients; this was adjacent to bone (paraskeletal) in 10% and not adjacent in 14% [23]. Rasche et al. [21] screened their myeloma registry for patients who developed EMD relapse, and reported an incidence rate of 6.7% (24/357 patients). In a Mayo Clinic including 174 patients with RRMM enrolled in a phase 2 clinical trial [30], 16 patients (9.2%) were found to have EMD (3 patients [1.7%] at the time of diagnosis, 13 [7.5%] during the course of treatment).

Typical sites of occurrence
Plasmacytomas can be found in virtually any area of any tissue in the body. A recent real-world retrospective study of 226 MM patients presenting with plasmacytomas included 176 patients with EMD [31]. The most common sites of EMD occurrence were skin/muscle (24%), pleura (12%), lymph nodes (10%), liver (9%), and CNS (6%). Different sites appear to be involved in EMD identified at MM diagnosis and at relapse, with skin the most
commonly involved tissue in NDMM [2, 20, 28, 29]. In RRMM, sites involved include liver, kidneys, lymph nodes, CNS, breast, pleura, and pericardium [2, 28, 29].

Prognosis
A retrospective study of transplant-eligible patients with MM compared survival outcomes in patients who had EMD (n = 17), bone-related plasmacytomas (n = 22), and no plasmacytoma involvement (n = 141) at diagnosis [32]. Five-year overall survival (OS) was 63% in patients who had bone-related plasmacytomas, 63% in patients who had EMD, and 80% in patients without plasmacytomas at diagnosis (p = 0.02). Five-year disease-free survival was 47% in patients who had bone-related plasmacytomas, 35% in patients with EMD, and 54% in MM patients who did not have plasmacytomas (p = 0.15).

Moreau et al. [33] found that absence of EMD at diagnosis was an independent prognostic factor for longer progression-free survival (PFS; p < 0.001) and OS (p = 0.004). By multivariate analysis, the hazard ratios (HRs) for PFS and OS were 3.394 (95% CI 2.055–5.606) and 3.894 (95% CI 1.540–9.851), respectively. Another study assessed predictors of inferior clinical outcome in patients (n = 51) with standard-risk MM [34]; on univariate analysis, EMD was associated with significantly shorter OS (HR 3.05; 95% CI 0.57–16.29; p = 0.02).

Treatment outcomes
**EMD in patients with NDMM.** Currently available data for treatment outcomes in patients with NDMM and EMD are summarized in Table 3.

The recent meta-analysis of eight trials of IMiD- or PI-based therapy in patients (n = 2332) with NDMM [26] included 267 patients with soft-tissue plasmacytomas (paraskeletal, n = 243; EMD, n = 12; not classified, n = 12). Median PFS was 26.1 months and 25.2 months in patients with EMD and patients without plasmacytomas, respectively; median OS was 70.1 months (EMD) and 79.9 months (no plasmacytomas). Batsukh et al. [35] retrospectively assessed outcomes in 64 NDMM patients with soft-tissue plasmacytomas who were treated with various regimens containing novel agents. Median PFS was similar (approximately 16 months) for patients with bone-related plasmacytomas and EMD, while median OS was significantly shorter (27.8 vs 54.2 months, p = 0.033) in the EMD group (mainly due to shorter PFS after first relapse).

Beksac et al. [31] conducted a multicenter, multinational retrospective study of 226 MM patients with plasmacytoma involvement; 176 had EMD (n = 92 at MM diagnosis, n = 84 at relapse) and 50 had paraskeletal plasmacytomas (n = 38 at MM diagnosis, n = 12 at relapse). The entire group received a median two lines of treatment and autologous SCT (44%) following their
Table 2. Incidence rates of EMD in studies of patients with MM.

| Reference                  | No. of patients | Time period covered | Diagnostic approach                                                                 | Incidence        |
|----------------------------|-----------------|---------------------|---------------------------------------------------------------------------------------|------------------|
| Montefusco et al. [26]     | 2322            | 2010–2018 (across all studies) | Skeletal survey, MRI, or CT; and/or physical examination                                | NDMM: 0.5%       |
| Gagelmann et al. [28]      | 3744            | 2005–2014           | NR                                                                                   | NDMM: 3.7%       |
| Deng et al. [18]           | 834             | 1993–2013           | X-ray, US, CT, physical examination; histologically confirmed where possible           | NDMM: 4.8%       |
| Weinstock et al. [29]      | 663             | 2005–2011           | Pathological or radiological evidence of EMD at any time following the initial diagnosis of MM | RRMM: 8.3%       |
| Pour et al. [23]           | 226             | 2005–2008           | US, CT, or MRI                                                                        | RRMM: 14%        |
| Rasche et al. [21]         | 357             | 2007–2010           | Cytology, biopsy of clinical/radiological lesions                                      | RRMM: 6.7%       |
| Short et al. [30]          | 174             | 2007–2011           | PET/CT                                                                                | NDMM: 1.7%       |

CT computed tomography, MRI magnetic resonance imaging, NR not reported, PET positron emission tomography, US ultrasound.

Table 3. Treatment outcomes in patients with NDMM and EMD.

| Reference                  | Study type                  | Total number of patients/number with EMD | Time period covered          | Treatments                                                                 | PFS               | OS               |
|----------------------------|-----------------------------|------------------------------------------|-----------------------------|---------------------------------------------------------------------------|-------------------|------------------|
| Montefusco et al. [26]     | Meta-analysis of 8 trials   | 267 EMD, n = 12                          | 2010–2018 (across all studies) | IMiD-based therapy (n = 166), PI-based (n = 66), IMiD + PI-based (n = 35) | Median (95% CI): 26.1 months (8.0–NR) | 2-year: 35% Median (95% CI): 70.1 months (16.9–NR) |
| Batsukh et al. [35]        | Retrospective               | 64 EMD, n = 22                           | 2009–2016                   | Bortezomib/dexamethasone (n = 7), Thalidomide/dexamethasone (n = 23), Bortezomib/thalidomide/dexamethasone (n = 11), Bortezomib/melphalan/prednisone (n = 23), Lenalidomide/dexamethasone (n = 1), Mephalan/prednisolone or dexamethasone (n = 6), ASCT (n = 28) | Median (95% CI): 16.0 months (5.8–26.2) | Median (95% CI): 27.8 months (5.8–26.5) |
| Beksac et al. [31]         | Retrospective               | 130 EMD, n = 92                          | 2010–2017                   | Median two lines of treatment and ASCT (44%)                             | Median (95% CI): 38.9 months (23.6–54.2) | Median (95% CI): 46.5 months (25.5–67.5) |
| Gagelmann et al. [28]      | EBMT registry analysis      | 488 EMD, n = 87                          | 2003–2014                   | Induction with bortezomib (n = 355) vs non-bortezomib (n = 133), Transplants: autologous (n = 373) or tandem autologous (n = 84) or autologous-allogeneic transplant (n = 31) | 3-year (range): 39% (27–52) | 3-year (range): 60% (48–73) |
| Gagelmann et al. [28]      | EBMT registry analysis      | 682 EMD, n = 139                         | 2005–2014                   | Upfront single ASCT within 12 months of diagnosis or a tandem ASCT within 6 months from first ASCT as first-line therapy | 3-year (range): 39.9% (30.3–49.5) | 3-year (range): 58.0% (48.1–67.9) |

ASCT autologous stem-cell transplantation, EBMT European Society for Blood and Marrow Transplantation, EMD extramedullary disease, IMiD immunomodulatory drugs, OS overall survival, PFS progression-free survival, PI proteasome inhibitor.
plasmacytoma diagnosis. PFS and OS were 38.9 months and 46.5 months for EMD at diagnosis and 51.7 months (p = 0.034) and not reached (p = 0.002) for paraskeletal plasmacytomas.

Gagelmann et al. [36] analyzed clinical and cytogenetic data from 488 patients with NDMM and soft-tissue plasmacytomas (paraskeletal, n = 374; EMD, n = 87; both, n = 27) who underwent SCT. High-risk cytogenetics were identified in 41% of the patients and found more frequently in those with EMD. Outcomes following single autologous SCT were significantly worsened in the presence of high-risk cytogenetic abnormalities, whereas a tandem autologous transplant strategy was shown to offset the poor prognosis. An analysis of 3744 patients with NDMM found no difference in 3-year PFS following first-line autologous SCT between those with single-site plasmacytomas (any location) and patients without plasmacytomas [28]. However, single EMD involvement was associated with worse 3-year OS compared with no plasmacytomas, which worsened still further when multiple sites of organs were involved. Note that there is some overlap in the patients included in these two studies [28, 36].

**EMD in patients with RRMM.** A summary of currently available data for treatment outcomes in patients with RRMM and EMD is provided in Table 4.

In a retrospective study of 127 consecutive patients with hematogenous EM relapse [37], first treatments for EMD included PIs (50%), IMiDs (39%), monoclonal antibodies (10%), and chemotherapy (53%). ORR (PIs (50%), IMiDs (39%), monoclonal antibodies (10%), and chemotherapy (53%). ORR (50%) was achieved in more than half (6/11) of the patients included in these two studies [28, 36].

**CNS involvement**

Available data for treatment outcomes in patients with CNS soft-tissue involvement are summarized in Table 5. In a large (N = 172), retrospective, multi-institutional study, overall median OS after onset of CNS involvement was 6.7 months [48]. Median OS was 2 months for those untreated and 8 months for patients who received treatment for CNS disease. Another study of 16 patients treated with different combinations of systemic therapy, intrathecal chemotherapy, and radiotherapy highlighted a dismal outcome for patients with leptomeningeal involvement (median OS of 82 days) [49].

Paludo et al. [50] compared a cohort of MM patients with CNS involvement (n = 29) with a control population of patients without CNS involvement. OS from diagnosis of MM was shorter in the CNS-MM group than in the control group (median 40 months vs 93 months); OS from detection of CNS involvement was 3.4 months. In patients who underwent ASCT after CNS involvement (n = 7), median OS was 19 months (95% CI 10–67 months) from the detection of CNS involvement.

Katodritou et al. [51] retrospectively reviewed medical records of 31 patients with CNS-MM treated in centers from Greece. Both PFS and OS were significantly shorter in the patients treated for CNS-MM (n = 29) compared with the control group (MM with no CNS involvement), and treatment with novel agents did not confer a survival advantage. Another study retrospectively reviewed patients with CNS-MM (n = 35) identified from the University of Arkansas MM database. [52] Treatment comprised mainly systemic and/or intrathecal chemotherapy, and median OS was 4 months.

Yet another retrospective study, from a single center in Canada, identified 37 patients with CNS-MM [53]. Median OS was only 4.6 months, although nine patients had prolonged survival (median 17.1 months); these longer-term survivors were treated with radiotherapy, intrathecal chemotherapy, and IMiD-based regimens. Lee et al. [54] retrospectively analyzed 17 patients with CNS-MM, reporting a median OS of 4 months from time of CNS involvement. OS was significantly better in patients who received intrathecal chemotherapy than those who did not (20 months vs 2 months, respectively; p < 0.02). Another retrospective survey of
| Reference Study type | Total number of patients/ number with EMD | Time period covered | Treatments | PFS  | OS  | Other |
|----------------------|------------------------------------------|--------------------|------------|------|-----|-------|
| **Novel agents (various) and/or SCT**<br><br>Avivi et al. [37]<br>Retrospective<br>2010–2018 | 127 (all EMD) | First treatment included PIs (50%), IMiDs (39%), monoclonal antibodies (10%), and chemotherapy (53%) | – | – | 57% ORR (≥ PR) across all treatments |
| Rasche et al. [21]<br>Single-center registry | 24 (all EMD) | Radiotherapy (n = 16)<br>ASCT + intense dose chemotherapy (n = 6)<br>Bortezomib (n = 16)<br>Lenalidomide (n = 12)<br>Thalidomide (n = 8) | Median (95% CI): 2 months (0.08–3.92)<br>Median (95% CI): 7 months (3.56–10.43) | – | – |
| Beksac et al. [31, 38]<br>Retrospective | 96 EMD, n = 84 | Median two lines of treatment and ASCT (44%) | Median (95% CI): 9.1 months (11.6–15.6) | Median (95% CI): 11.4 months (0.6–16.2) | Complete remission rate: 9% (vs 54.5% in patients with paraskeletal, p < 0.001) |
| Short et al. [30]<br>Phase 2 trial | 16 (all EMD) | Pomalidomide + low-dose dexamethasone | – | Median: 16 months | – |
| **Pls**<br><br>Zhou et al. [39]<br>Retrospective | 45 EMD, n = 25 | Carfilzomib + dexamethasone-based | EMD significantly inferior PFS vs paraskeletal (p = 0.004) | EMD significantly inferior OS vs paraskeletal (p = 0.04) | – |
| Papanikolaou et al. [40]<br>Retrospective | 28 (all EMD) | At relapse: Bortezomib-containing regimens (32%)<br>Platinum-containing (21%)<br>Lenalidomide (21%)<br>VAD (8%) | – | Median following relapse: 5 months<br>Median from MM diagnosis: 38 months | – |
| **Chemotherapy/radiotherapy**<br><br>Rasche et al. [41]<br>Retrospective | 11 (all EMD) | Dexa-BEAM (including dexamethasone, carmustine, cytarabine, etoposide, and melphalan) | Median: 4 months | – | Objective response (≥ PR) achieved in 6/11 patients |
| Richardson et al. [42]<br>Phase 2 | 55 EMD, n = 27 | Patients enrolled between Dec 2016 and Oct 2019 | Melflufen + dexamethasone | – | – | ORR: Non-EMD, 32%<br>Paraskeletal, 25%<br>EMD, 22% |
| Wang et al. [43]<br>Single-center | 57 EMD, n = 17 | 2016–2018 | LCAR-B38M | Median: 8.1 months (vs 25 months in non-EMD; p < 0.001) | Median: 13.9 months (vs NR in non-EMD; p = 0.0019) | 82% ORR (≥ PR) vs 90% for non-EMD |

ASCT autologous stem cell transplantation, EMD extramedullary disease, MM multiple myeloma, NC not calculable, NR not reached, ORR overall response rate, OS overall survival, PFS progression-free survival, PR partial response, VAD vincristine/adriamycin/dexamethasone.
| Reference Study type | No. of patients | Time period covered | Treatments | PFS | OS |
|----------------------|----------------|---------------------|------------|-----|----|
| Bommer et al. [49]   | 16 (all LMM)   | 2005–2016           | Intrathecal chemotherapy, radiotherapy | –   | Median OS: 82 days (after LMM diagnosis) |
| Jurczyszyn et al. [48]| 172            | 1995–2014           | Systemic therapy (n = 117) Radiotherapy (n = 56) Intrathecal therapy (n = 49) Steroids only (n = 5) Mass resection (n = 1) SCT (n = 32) | –   | Median OS: 6.7 months (all patients) 2 months (untreated patients) 8 months (treated patients) |
| Paludo et al. [50]   | 29 (7 at initial diagnosis of MM, 22 at relapse) | 1998–2014 | Radiation therapy (n = 22) + adjuvant intrathecal chemotherapy (n = 6) Intrathecal + systemic therapy (n = 1) Systemic therapy (n = 2) Novel agents, including bortezomib (28%), thalidomide (14%), lenalidomide (10%), and pomalidomide (3%), administered after CNS involvement. ASCT after the diagnosis of CNS disease (24%) | Median OS: 40 months (24–56) | Median OS (95% CI): CNS involvement, 40 months (24–56) Control (no CNS involvement), 93 months (67–129) Patients with ASCT after CNS involvement, 19 months (10–67) |
| Katodritou et al. [51]| 31             | 2000–2013           | Bortezomib-based (n = 12) IMiD-based (n = 5) Chemotherapy alone (n = 8) Intrathecal infusions (n = 3) Additional radiotherapy (n = 9) | Median (95% CI) CNS involvement, 16 months (2–30.6) Control (no CNS involvement), 36 months (12–60) \( p = 0.004 \) | Median (95% CI) CNS involvement, 47 months (32–62) Control (no CNS involvement), 84 months (31–137) \( p = 0.01 \) |
| Abdallah et al. [52] | 35             | 1996–2012           | Chemotherapy, including intrathecal (n = 28) Intrathecal alone (n = 3) | –   | Median (range): 4 months (1–13) |
| Chen et al. [53]     | 37             | 1999–2010           | Intrathecal chemotherapy (81%) Cranial and/or spinal irradiation (78%) IMiDs (51%) Cisplatin-based (27%) Bortezomib (19%) Alkylators (11%) Dexamethasone alone (8%) ASCT (5%) | Median (95% CI) after CNS involvement: 3.1 months (2.0–6.0) | Median (95% CI) after CNS involvement: 4.6 months (2.8–6.7) |
| Lee et al. [54]      | 17             | 2000–2011           | Systemic pharmacotherapy Intrathecal chemotherapy and/or radiotherapy | –   | Median (range) after CNS involvement: 4 months (1–23) |
| Gazzetti et al. [55] | 12             | 2000–2010           | Systemic treatment Systemic treatment + radiotherapy Systemic + radiotherapy + intrathecal Radiotherapy + intrathecal Intrathecal (note: specific treatments received by patients with CNS-MM not specified) | –   | Median (range): 6 months (1–23) |

ASCT autologous stem cell transplantation, CNS central nervous system, IMiD immunomodulatory drug, LMM leptomeningeal myelomatosis, MM multiple myeloma.
50 patients with intracranial involvement in MM included 12 patients with CNS-MM [55]; within the subgroup of patients with CNS involvement, the median survival was 6 months.

**DISCUSSION**

The presence of soft-tissue plasmacytomas represents an aggressive form of MM, which can be found at the time of MM diagnosis or at relapse. Several different definitions of extramedullary involvement in MM or EMD have been proposed in the literature. We and others advocate that true EMD is restricted to plasmacytomas that arise due to hematogenous spread and have no contact with bony structures. Typical sites of EMD may vary according to the stage of MM. At diagnosis, EMD is typically found in skin; at relapse, typical sites involved include the liver, kidneys, lymph nodes, breast, pleura and pericardium, and the CNS.

In addition to the variation in definition, the published literature on soft-tissue plasmacytomas is difficult to navigate for several reasons: data may be reported for ‘mixed’ populations of patients with NDMM and RRMM; data may be reported for bone-related plasmacytomas and EMD combined; or a clear definition is lacking the type of plasmacytoma being studied. By including, as far as possible, only studies that clearly define the phase of MM and clearly specify EMD, this review differs from much of the previously published literature in this area.

The reported incidence of EMD varies considerably, and differences in diagnostic approach between studies are likely to contribute to this variability. In patients with NDMM, the reported incidence ranges from 0.5% to 4.8%, while in RRMM the reported incidence is 3.4–14%. Available data demonstrate that the prognosis is poor, and considerably worse than for MM without EMD. For patients with soft-tissue plasmacytomas, those with EMD typically have poorer outcomes than those with parakapital involvement. CNS involvement is rare, but prognosis is even more dismal than for EMD in other locations, particularly if there is leptomeningeal involvement.

The outcome of patients with EMD should be reported as a predefined subgroup in clinical trials. In this regard, the prospective IMAJEM study from the French group showed the prognostic impact of the presence of EMD [33]. In the CASSIOPEIA study, from the same group comparing bortezomib/thalidomide and dexamethasone with or without daratumumab as pretransplant induction regimen, a PET/CT substudy (CASSIOPET) is ongoing, which aims to investigate the prognostic impact of this antibody response to therapy, including MRD assessments, in patients with EMD [27]. Hopefully, the design of future trials will investigate the prognostic impact and treatment efficacy in patients with EMD.

Available data on treatment outcomes for EMD are almost entirely derived from retrospective studies. Some agents and combinations have shown a degree of efficacy but, as would be expected based on known prognoses, this is typically less than in MM patients with no extramedullary involvement. The paucity of prospective studies makes it difficult to justify strong recommendations for any treatment approach. The recent expert consensus review provided some possible treatment approaches for consideration [4]. For upfront treatment of EMD in transplant-ineligible patients, the addition of daratumumab to VMP or RVD was suggested. In transplant-eligible patients, intensive anti-myeloma/anti-lymphoma regimens (e.g. VTD/ or VRD/PACE combined with SCT) are proposed as a theoretical option [4]. Suggested treatments at relapse are also based on lymphoma-like regimens such as PACE, DECP, or Dexe-BEAM, although duration of response is typically ≤4 months. Beyond this, novel-agent combinations (e.g. carfilzomib-, selinexor-, or isatuximab-based) or newer/investigational agents (e.g. CAR-T, BITES, melflufen) may be considered [4]. For CNS involvement, some combination of IMID-based systemic therapy, intrathecal and radiation therapy appears to provide the best treatment outcome.

Current response criteria, including MRD assessment, should be applied in patients with EMD. As per the recent consensus on extramedullary involvement in MM, the first assessment of EMD identified by PET/CT (considering size and metabolic uptake) and/or MRI should be done at three months after treatment initiation and at physician discretion thereafter [4]. It is recommended that baseline and follow-up assessments should use the same imaging technique in order to minimize the inter-technique variability. To declare complete remission (CR), all evidence of EMD must have disappeared according to the standardization for metabolic CR definition recently proposed [25], as well as the disappearance of the serum and urine M-protein by immunofixation [56]. In addition, a bone marrow negative for MRD by flow cytometry (FC) will define not only CR, but also MRD negativity (so-called double negative at EM involvement PET/CT and at bone marrow FC [27, 33]. There is an expectation that liquid biopsy with MRD assessment in peripheral blood may help to further ensure disease eradication in all compartments; however, data on this remains limited.

Prospective data from patients with clearly defined EMD are important for the optimal evaluation of treatment outcomes. Conducting trials that are adequately powered to assess outcomes is a challenge in this uncommon group of patients. In such cases, the inclusion of these patients in trials to allow subgroup assessment of treatment effects with a priori hypotheses may provide the best attainable evidence. There are signs from trials of the next wave of MM treatments that patients with EMD are at last being studied in greater detail, and this is a trend that should be encouraged. Widespread adoption of specific response criteria based on both morphological and functional evaluation, such as those proposed recently by Zamagni et al. [25], will also be important for understanding and comparing the impact of different treatments on EMD.

**REFERENCES**

1. Rajkumar SV, Dimopoulos MA, Palumbo A, Bladé J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–548.
2. Bladé J, Fernández de Larrea C, Rosiñol L, Cibeira MT, Jiménez R, Powles R. Soft-tissue plasmacytomas and EMD combined; or a clear definition, the published literature
3. Liu Y, Jelloul F, Zhang Y, Bhavsar T, Ho C, Rao M, et al. Genetic basis of extramedullary involvement in MM, the median survival was 6 months.
4. Rosiñol L, Bekssac M, Zamagni E, Van de Donk NWJ, Anderson KC, Badros A, et al. Expert review of soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br. J. Haematol. 2021;10.1111/bjh.17338.
5. Rosiñol L, Fernández de Larrea C, Bladé J. Extramedullary myeloma spread triggered by surgical procedures: an emerging entity? Acta Haematol 2014;132:36–8.
6. Muchtar E, Raanan P, Yeshurun M, Shpilberg O, Magen-Nativ H. Myeloma in scar tissue—an underreported phenomenon or an emerging entity in the novel agents’ era? A single center series. Acta Haematol 2014;132:39–44.
7. Weinstock M, Ghobrial IM. Extramedullary multiple myeloma. Leuk Lymphoma. 2013;54:1135–41.
8. Sevcikova S, Minarik J, Stork M, Jelinek T, Pour L, Hajek R. Extramedullary disease in multiple myeloma - controversies and future directions. Blood Rev. 2019;33:52–9.
9. Jagosky MH, Usmani SZ. Extramedullary disease in multiple myeloma. Curr Hematol Malig Rep. 2020;15:62–71.
10. Caers J, Paiva B, Zamagni E, Leelu T, Bladé J, Kristinsson SY, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;11:10.
11. Fernández de Larrea C, Kyle RA, Durie BGM, Ludwig H, Usmani S, Vesole DH, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013;27:780–91.
12. Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood. 2016;127:971-6.
13. Bhutani M, Foureur DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia. 2020;34:1-20.
14. Chang H, Sloan S, Li D, Stewart AK. Multiple myeloma involving central nervous system: high frequency of 17p13 (p53) deletions. Br J Haematol. 2014;167:280-4.
15. López-Lezón L, Gutiérrez NC, García JL, Mateos MV, Flores T, San Miguel JF. P53 deletion may drive the clinical evolution and treatment response in multiple myeloma. Eur J Haematol. 2010;84:359–61.
16. Sheth N, Yeung J, Chang H. P53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. Leuk Res. 2009;33:1357–60.
17. Billecke L, Murga Penas EM, May AM, Engelhardt N, Nagler A, Leiba M, et al. Cyto genetics in multiple myeloma patients progressing into extramedullary disease. Br J Haematol. 2013;161:87-94.
18. Deng S, Xu Y, An G, Sui W, Zou D, Zhao Y, et al. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases. Clin Lymphoma Myeloma Leuk. 2015;15:286–91.
19. Katodritou E, Gastari V, Verrou E, Hadjiaggelidou C, Varthaliti M, Georgiadou S, et al. Incidence and clinical features of extramedullary multiple myeloma in patients with an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome? Leuk Res. 2009;33:137-40.
20. Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97:1761–7.
21. Rasche L, Bernard C, Topp MS, Kapp M, Duell J, Wesemeier C, et al. Features of extramedullary myeloma relapse: high proliferation, minimal marrow involve- ment, adverse cytogenetics: a retrospective single-center study of 24 cases. Ann Hematol. 2012;91:1031–7.
22. Varettioni M, Corsa A, Pica G, Mangiacavallo S, Pascotto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010;21:325–30.
23. Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, et al. Role of dynamic contrast-enhanced sonography for characterization and monitoring of extramedullary myeloma. Haematologica. 2016;99:360–4.
24. Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, et al. Role of new approaches in advanced multiple myeloma relapse. Haematologica 2014;99:360–1.
25. Basso R, Sauri S, Chiovato L, Zangari M, Zangari M, Pasquale M, et al. Clinical and genetic characteristics of patients with extramedullary disease: a single institution experience. Blood. 2014;123(17):3357-63.
26. Moreau P, Göker H, Demiroglu C, Varthaliti M, Georgiadou S, et al. Evaluation of the survival outcomes of multiple myeloma patients included in the IFM/DFCI 2009 trial: results of the IMAJEM study. J Clin Oncol. 2017;35:2991–8.
27. Badar T, Sauri S, Bashir Q, Shah N, Al-Atrash G, Hosig C, et al. Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. Eur J Haematol. 2017;98:263–8.
28. Batsukh K, Lee SE, Min GJ, Park SS, JeonYW, Yoon JH, et al. Distinct clinical outcomes between paramedullary and extramedullary lesions in newly diagnosed multiple myeloma. Immune Netw. 2017;17:250–60.
29. Gabegnan M, Eikema DJ, Koster L, Caillot D, Piolletti P, Lleonart JB, et al. Tandem autologous stem cell transplantation improves outcomes in newly diagnosed multiple myeloma with extramedullary disease and high-risk cyto- genetics: a study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2019;25:2134–42.
30. Avivi I, Cohen YC, Suska A, Shragai T, Mikala G, Garderet L, et al. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. Ann J Hematol. 2019;94:1132–40.
31. Bekas C, Seval GC, Kanaillis N, Corui D, Rosiilh L, Ozet G, et al. A real work multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica. 2020;106:1228.
32. Zhuo X, Flüchter P, Nickel K, Meckel K, Messerschmidt J, Böckle D, et al. Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease. Cancers (Basel). 2020;12:1035.
33. Papanikolau X, Repoussis P, Tzenou T, Maltezas D, Kotsopoulos M, Megalakaki K, et al. Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse. Leuk Lymphoma. 2013;54:1459–64.
34. Rasche L, Striffer S, Drell J, Rosenwald A, Buck A, Maeder U, et al. The lymphoma-like polychemotherapy regimen “Dexa-BEAM” in advanced and extramedullary multiple myeloma. Ann Hematol. 2014;93:1207–14.
35. Richardson PG, Mateos MV, Orlo A, Larroca A, Cavo M, Rodriguez-Otero P, et al. HORIZON (OP-106): melflufen plus dexamethasone (dex) in 55 patients (pts) with relapsed/refractory multiple myeloma with extramedullary disease (EMD)—subgroup analysis. Blood. 2020;136(Supplement 1):15–17.
36. Wang B, Liu J, Zhao WH, Chen YX, Cao XM, Yang Y, et al. Chimeric antigen receptor T cell therapy in the relapsed or refractory multiple myeloma with extramedullary disease-a single institution observation in China. Blood. 2020;136(Suppl 1):6.
37. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726–37.
38. Munshi NC, Anderson LD Jr, Shah N, Madduri S, Berdeja J, Lonial S, et al. Idecabtagene vilucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705–16.
39. Usmani SZ, Berdeja JG, Madduri D, Jakubowiak AJ, Agha ME, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric anti- gen receptor T-cell therapy, in relapsed/refractory multiple myeloma: updated results from CARTITUDE-1. Presented at ASCO 2021. Available from: https://www.oncologysciencehub.com/OncologyAM2021/cilta-cel/Usmani/ (Accessed June 2021).
40. Deng H, Liu M, Yuan T, Zhang H, Cui R, Li J, et al. Efficacy of humanized Anti- BCMA CAR T cell therapy in relapsed/refractory multiple myeloma patients with and without extramedullary disease. Front Immunol. 2021;12:205751.
41. Jurczyszyn A, Grzasko N, Gozetti A, Czeplej J, Cerase A, Hungria V, et al. Central nervous system involvement by multiple myeloma: a multi-institutional retro- spective study of 172 patients in daily clinical practice. Am J Hematol. 2016;91:575–80.
42. Bommer M, Kull M, Teleau V, Schwarzwalder P, Feuring-Buske M, Koenen J, et al. Lepptomeningeal myelomatosis: a rare but devastating manifestation of multiple myeloma diagnosed using cytology, flow cytometry, and fluorescent in situ hybridization. Acta Haematol. 2018;139:247–54.
43. Paladino J, Painuly U, Kumar S, Gonsalves WI, Rajkumar V, Buadi F, et al. Myeloma involvement of the central nervous system. Clin Lymphoma Myeloma Leuk. 2016;16:644–54.
44. Katodritou E, Terpos E, Kastritis E, Delimpasis S, Symeonidis AS, Repousis P, et al. Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group Experience. Ann Hematol. 2015;94:2033–42.
45. Abdallah AQ, Atrash S, Shahid J, Zameel M, Graziutti M, Apevokin S, et al. Patterns of central nervous system involvement in relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014;14:211–4.
46. Chen CI, Masih-Khan E, Jiang H, Rabea A, Cseti-Gazdewich C, Jimenez-Zepeda VH, et al. Central nervous system involvement with multiple myeloma: longitudinal
survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents. Br J Haematol. 2013;162:483–8.

54. Lee D, Kaff A, Low M, Gangatharan S, Ho P, Bajel A, et al. Central nervous system multiple myeloma-potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains. Br J Haematol. 2013;162:371–5.

55. Gozzetti A, Cerase A, Lotti F, Rossi D, Palumbo A, Petrucci MT, et al. Extra-medullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients. Cancer. 2012;118:1575–84.

56. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e346.

ACKNOWLEDGEMENTS
Medical writing support was provided by Tony Reardon of Aura, and Jaya Shumoogam of Ascend, both divisions of Spirit Medical Communications Group Limited, funded by Oncopeptides. Medical writing support was funded by Oncopeptides.

AUTHOR CONTRIBUTIONS
J.B. wrote the first draft and incorporated the comments by the co-authors in all subsequent drafts. M.B., J.C., A.J., M.v.L.-T., P.M., Leo Rasche, Laura Rosiñol, S.Z.U., E.Z., and P.R. made a number of comments on the first and subsequent drafts. All authors approved the final version of the manuscript.

COMPETING INTERESTS
J.B. has received speaker/lecture honoraria from Janssen, Celgene/BMS, Amgen, Takeda, and Oncopeptides. M.B. has received speaker honoraria from Amgen, Oncopeptides, Janssen, Sanofi, and Takeda. Jo Caers has received research funding from Takeda and Janssen; and honoraria from Janssen, Amgen, BMS-Celgene, and Sanofi. A.J. has received honoraria from Janssen, BMS, Takeda, Sanofi, GSK, Karyopharm, Oncopeptides, and Amgen. M.v.L.-T. has received research funding from Celgene and Oncopeptides; and honoraria from BMS/Celgene, Oncopetides, Janssen, GSK, and Takeda. Philippe Moreau has received honoraria from Janssen, Celgene, Amgen, AbbVie, Oncopeptides, and Sanofi. Leo Rasche has received honoraria from BMS/Celgene, Sanofi, GSK, Oncopeptides, and Janssen. Laura Rosiñol has received speaker honoraria from Janssen, Celgene, Amgen, Takeda, GSK, and Sanofi. S.Z.U. has received research funding and/or honoraria from Amgen, Celgene, Janssen, Takeda, BMS, Oncopeptides, and Sanofi. E.Z. has received honoraria from, and been an advisory board member for, Janssen, BMS, Takeda, Sanofi, GSK, Karyopharm, Oncopetides, and Amgen. P.R. has received institutional research support from Oncopeptides, Celgene/BMS, Takeda, and Karyopharm. He has received honoraria for his role as an Advisory Committee member from Karyopharm, Oncopetides, Celgene/BMS, Takeda, Janssen, Sanofi, Secura Bio, GSK, Regeneron, AstraZeneca, and Protocol Intelligence.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Joan Bladé.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022